Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMBZWQL)

Drug Name
Clemastine Drug Info
Synonyms
Clemastina; Clemastinum; Meclastin; Meclastine; Mecloprodin; Tavegyl; Tavist; CLEMASTINE FUMARATE; HS 592; Clemastina [INN-Spanish]; Clemastine [USAN:BAN]; Clemastinum [INN-Latin]; HS-592; Tavegyl (TN); Tavist (TN); Tavist (*Fumarate*); (+)-(2R)-2-(2-(((R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine; (+)-(2R)-2-[2-[[(R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine; (2R)-2-(2-{[(1R)-1-(4-chlorophenyl)-1-phenylethyl]oxy}ethyl)-1-methylpyrrolidine; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine; (2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine; 2(R)-[2-[(1R)-(4-Chlorophenyl)-1-phenyl-ethoxy]ethyl-1-methylpyrrolidine; 2-(2-(4-Chlor-alpha-methylbenzhydryloxy)ethyl)-1-methylpyrrolidin
Therapeutic ClassAntiallergic Agents
Cross-matching ID
PubChem CID
26987
ChEBI ID
CHEMBL1626
CAS Number
CAS 15686-51-8
TTD Drug ID
D0C5XC
VARIDT Drug ID
DR00796
ACDINA Drug ID
D00135

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.57 0.00e+0 19/20 (95%) MSMO1;SQLE;LSS;...
Terpenoid backbone biosynthesis 2.16 0.00e+0 18/22 (81.82%) HMGCS1;IDI1;FDPS;...
Biosynthesis of unsaturated fatty acids 2.12 0.00e+0 21/27 (77.78%) SCD;FADS1;ELOVL6;...
Synthesis and degradation of ketone bodies 2.02 3.52e-3 9/10 (90%) HMGCS1;ACAT2
Fatty acid biosynthesis 1.98 2.82e-3 16/18 (88.89%) FASN;ACSL3;ACACA;...
PPAR signaling pathway 1.96 2.35e-3 66/74 (89.19%) HMGCS1;SCD;ACSL3;...
Ferroptosis 1.81 9.05e-3 36/41 (87.8%) ACSL3;HMOX1;SLC7A11;...
Sphingolipid metabolism 1.80 7.92e-3 32/49 (65.31%) NEU1;PLPP3;PLPP2;...
Butanoate metabolism 1.78 1.17e-2 23/28 (82.14%) HMGCS1;ACAT2;AACS
RNA transport -1.80 2.88e-2 128/186 (68.82%) EIF4E2;FUS;NUP88;...
Drug metabolism -1.92 5.32e-3 78/151 (51.66%) XDH;CYP2C19;RRM2;...
Spliceosome -2.00 3.32e-3 101/150 (67.33%) LSM2;FUS;RBM8A;...
Ribosome biogenesis in eukaryotes -2.02 0.00e+0 52/108 (48.15%) NHP2;RRP7A;SNU13;...
Asthma -2.02 0.00e+0 25/31 (80.65%) CD40LG;IL13;HLA-DOB;...
Systemic lupus erythematosus -2.08 0.00e+0 45/135 (33.33%) CD40;C3;FCGR2A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 4uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 10uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H